Sana Biotechnology, Inc.

Sana Biotechnology, Inc.

SANANYSE / NASDAQHealthcareSmall cap

$1.59-$0.15 (-8.6%)

Last close · Data as of Nov 20, 2026

Market cap
$823.7M
P/E
-3.4x
EV / EBITDA
-4.3x
Revenue
$0.00
ROCE
-60.8%

-50.8% over the last year

Sana Biotechnology, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-32.6%
3M
-57.5%
6M
-48.9%
1Y
-50.8%
5Y
Hidden
  • This period includes a one-day price step on 8 Jan 2025 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$0.15 (-8.6%) from $1.74 to $1.59 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in SANA, bought on each weekday since 2021.

News & filings

What Sana Biotechnology filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 244 million US dollars in fiscal 2025.

Strengths

No strength stands out for this company on the data on file.

  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.

Read moreShow less

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Sector
Healthcare
Shares outstanding
266.7M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$823.7M
P/E
-3.4x
P/B
5.1x
EV / EBITDA
-4.3x
52-week high
$5.18
52-week low
$1.59

Profitability

ROE
-151.8%
ROCE
-60.8%
ROIC
-96.8%
ROA
-58.6%

Growth

Revenue
$0.00
Net profit growth, 1Y
-8.5%
Free cash flow
-$144.8M

Solvency

Current ratio
1.89
Debt / Equity
0.49
Debt / Assets
0.19
CFO / Net profit
0.59
Cash / Market cap
8.7%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Sana Biotechnology, Inc. revenue and net profit by fiscal year
Sana Biotechnology, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$269.5M
FY2023$0.00-$283.3M
FY2024$0.00-$266.8M
FY2025$0.00-$244.2M

Cash flows

FY2025: -$143.8M from operations, -$144.8M free after investment (dashed).

Sana Biotechnology, Inc. operating and free cash flow by fiscal year
Sana Biotechnology, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$290.1M-$310.9M
FY2023-$253.6M-$273.6M
FY2024-$223.2M-$256.6M
FY2025-$143.8M-$144.8M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$193.0M
Net profit
-$244.2M
Cash from operations
-$143.8M
Free cash flow
-$144.8M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$193.0M-$244.2M-$144.8M-151.8%—-8.5%

Monthly returns

Month-by-month returns of SANA across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$416.9M
Liabilities$256.0M
Equity$160.9M
Paid-in capital$2.0B
Retained earnings-$1.8B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; SANA highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Sana Biotechnology, Inc., ORIC Pharmaceuticals, Inc., LB Pharmaceuticals Inc, Replimune Group, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Sana Biotechnology, Inc.SANAthis company$823.7M-3.4x5.1x-151.8%-4.3x
Theravance Biopharma, Inc.TBPH$843.9M8.0x2.8x35.7%5.3x
Janux Therapeutics, Inc.JANX$839.1M-7.4x0.9x-11.9%-5.2x
ORIC Pharmaceuticals, Inc.ORIC$830.2M-6.4x2.2x-33.7%-5.6x
LB Pharmaceuticals IncLBRX$828.8M-32.9x2.8x-8.4%-19.4x
Amphastar Pharmaceuticals, Inc.AMPH$824.5M8.4x1.0x12.4%6.2x
Replimune Group, Inc.REPL$815.0M-3.3x2.0x-59.5%-3.3x
Esperion Therapeutics, Inc.ESPR$805.8M——7.5%13.9x
Lumexa Imaging Holdings, Inc.LMRI$791.7M-16.8x1.4x-8.0%12.0x
Peer median—-6.4x2.0x-8.2%1.0x

Year-to-date ROI

SANA since 1 January, against earlier years.

Historical volatility

SANA's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2025
Operating expensesOperating Expense$205.7M
Research and developmentResearch And Development$161.4M
Total expensesTotal Expenses$205.7M
Pretax incomePretax Income-$244.2M

Learn while you research

Academy chapters picked for Sana Biotechnology, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →